Microbot Medical Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Harel Gadot

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	29.0%
Dienstverband CEO	14.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	6.6yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Harel Gadot's beloning veranderd ten opzichte van Microbot Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$11m
Jun 30 2024	n/a	n/a	-US$10m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$1m	US$373k	-US$11m
Sep 30 2023	n/a	n/a	-US$11m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$13m
Dec 31 2022	US$2m	US$514k	-US$13m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$2m	US$534k	-US$11m
Sep 30 2021	n/a	n/a	-US$10m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	US$2m	US$450k	-US$9m
Sep 30 2020	n/a	n/a	-US$8m
Jun 30 2020	n/a	n/a	-US$8m
Mar 31 2020	n/a	n/a	-US$7m
Dec 31 2019	US$1m	US$360k	-US$7m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$1m	US$360k	-US$7m
Sep 30 2018	n/a	n/a	-US$7m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$718k	US$389k	-US$8m

Compensatie versus markt: De totale vergoeding ($USD 1.28M ) Harel } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.54K ).

Compensatie versus inkomsten: De vergoeding van Harel is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Harel Gadot (51 yo)

14.8yrs

Tenure

US$1,284,123

Compensatie

Mr. Harel Gadot is the Founder of MEDX Ventures Group LLC and serves as its Chairman. Mr. Gadot has been the Chief Executive Officer and President of Microbot Medical Inc. since November 28, 2016 and its C...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Harel Gadot	Co-Founder	14.8yrs	US$1.28m	geen gegevens
Yoseph Bornstein	Co-Founder & Independent Director	14.8yrs	US$74.12k	0% € 0
Rachel Vaknin	Chief Financial Officer	2.6yrs	US$289.50k	0% € 0
Simon Sharon	CTO & GM of Microbot Israel	6.6yrs	US$469.93k	0% € 0
Juan Diaz-Cartelle	Chief Medical Officer	less than a year	geen gegevens	0% € 0

6.6yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CY9D is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Harel Gadot	Co-Founder	10.3yrs	US$1.28m	geen gegevens
Yoseph Bornstein	Co-Founder & Independent Director	8yrs	US$74.12k	0% € 0
Scott Burell	Independent Director	8yrs	US$76.00k	0% € 0
Ajay Wakhloo	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
Stephen Solomon	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
Tal Wenderow	Independent Director	4.3yrs	US$73.70k	0% € 0
Giora Weisz	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
Martin Madden	Independent Director	7.8yrs	US$76.00k	0% € 0
Prattipati Laxminarain	Independent Director	6.9yrs	US$72.25k	0% € 0
Eyal Morag	Member of Scientific Advisory Board	7yrs	US$511.87k	geen gegevens
Aileen Stockburger	Independent Director	4.7yrs	US$75.01k	0% € 0
Dmitry Rabkin	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CY9D wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Microbot Medical Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Microbot Medical Inc., Annual General Meeting, Dec 17, 2024

Microbot Medical Inc. Announces Executive Changes

Microbot Medical Inc., Annual General Meeting, Nov 02, 2023

Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board

High number of new directors

Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board

Recent updates

New major risk - Financial position

Microbot Medical Inc., Annual General Meeting, Dec 17, 2024

Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million.

Microbot Medical Inc. announced that it has received $1.762502 million in funding

New major risk - Shareholder dilution

Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.

New major risk - Share price stability

Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters

New major risk - Shareholder dilution

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met

Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Executive Changes

Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company

Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System

Microbot Medical Inc., Annual General Meeting, Nov 02, 2023

Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board

Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office

New major risk - Shareholder dilution

Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System

LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process

Microbot Medical Inc. announced delayed 10-Q filing

Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System

Microbot Medical Inc. Announces Final Data from Its Recent Animal Study

Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization

Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel

Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance

High number of new directors

Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System

Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board

Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System

Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System

Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System

Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop.

Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment

Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board

Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board

Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System

Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board

Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System

Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month

Microbot Medical Inc., Annual General Meeting, Sep 21, 2022

High number of new directors

High number of new directors

Microbot Medical Inc. Announces Executive Changes

Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States

Microbot Medical Inc. Secures Patent Allowance in China and Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done’ Technology

New 90-day high: €8.75

Microbot Medical Announces Successful Outcome of Its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt

New 90-day high: €7.00

Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with Liberty Robotic System

New 90-day low: €5.55

Microbot Medical Inc. Announces Successful Animal Study Utilizing Its Liberty™ Robotic System

New 90-day low - €5.40

New 90-day high - €6.90

Analyse CEO-vergoeding

CEO

Tenure

Compensatie